These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20171390)

  • 1. An endothelin antagonist for resistant hypertension.
    Dhaun N; Goddard J; Webb DJ
    Lancet; 2010 Feb; 375(9715):635; author reply 636-7. PubMed ID: 20171390
    [No Abstract]   [Full Text] [Related]  

  • 2. An endothelin antagonist for resistant hypertension.
    O'Brien E
    Lancet; 2010 Feb; 375(9715):636; author reply 636-7. PubMed ID: 20171394
    [No Abstract]   [Full Text] [Related]  

  • 3. An endothelin antagonist for resistant hypertension.
    Naunton M
    Lancet; 2010 Feb; 375(9715):636; author reply 636-7. PubMed ID: 20171393
    [No Abstract]   [Full Text] [Related]  

  • 4. An endothelin antagonist for resistant hypertension.
    Bharti B; Bharti S
    Lancet; 2010 Feb; 375(9715):635; author reply 636-7. PubMed ID: 20171391
    [No Abstract]   [Full Text] [Related]  

  • 5. Darusentan: a new perspective for treatment of resistant hypertension?
    Enseleit F; Lüscher TF; Ruschitzka F
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1255-63. PubMed ID: 18616421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial.
    Bakris GL; Lindholm LH; Black HR; Krum H; Linas S; Linseman JV; Arterburn S; Sager P; Weber M
    Hypertension; 2010 Nov; 56(5):824-30. PubMed ID: 20921430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of darusentan: a novel endothelin receptor antagonist.
    Epstein BJ
    Ann Pharmacother; 2008 Jul; 42(7):1060-9. PubMed ID: 18523233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis.
    Yuan W; Cheng G; Li B; Li Y; Lu S; Liu D; Xiao J; Zhao Z
    Blood Press; 2017 Jun; 26(3):139-149. PubMed ID: 27808564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin-A receptor antagonist combined with hydralazine improves survival and renal function in hypertensive rats.
    Münter K; Hergenröder S; Kirchengast M
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S245-8. PubMed ID: 9595450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats.
    Schiffrin EL; Turgeon A; Deng LY
    Br J Pharmacol; 1997 Jul; 121(5):935-40. PubMed ID: 9222550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DORADO: opportunity postponed: lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension.
    Webb DJ
    Hypertension; 2010 Nov; 56(5):806-7. PubMed ID: 20921424
    [No Abstract]   [Full Text] [Related]  

  • 12. Endothelin receptor blockade in congestive heart failure.
    Cheng TO
    Circulation; 2001 Oct; 104(18):E96. PubMed ID: 11684644
    [No Abstract]   [Full Text] [Related]  

  • 13. Endothelin A antagonist LU-135252 and trandolapril in the treatment of the Cohen-Rosenthal diabetic hypertensive rat.
    Hofman C; Gabai E; Peleg E; Munter K; Rosenthal T
    Blood Press; 2005; 14(2):114-9. PubMed ID: 16036489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistant hypertension: an unmet treatment need.
    Williams B
    Lancet; 2009 Oct; 374(9699):1396-8. PubMed ID: 19748666
    [No Abstract]   [Full Text] [Related]  

  • 15. [Trend of research and development of antihypertensive agents].
    Imura Y
    Nihon Rinsho; 2006 Jul; 64 Suppl 5():583-7. PubMed ID: 16895229
    [No Abstract]   [Full Text] [Related]  

  • 16. Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension.
    Enseleit F; Lüscher TF; Ruschitzka F
    Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):231-40. PubMed ID: 20660536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Endothelin and essential hypertension].
    Kataoka K; Kurihara Y; Kurihara H
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():640-3. PubMed ID: 15506465
    [No Abstract]   [Full Text] [Related]  

  • 18. Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.
    Mucke HA
    IDrugs; 2009 Jun; 12(6):366-75. PubMed ID: 19517317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bosentan in essential hypertension.
    Haynes WG; Ferro CJ; Webb DJ
    N Engl J Med; 1998 Jul; 339(5):346; author reply 347. PubMed ID: 9696644
    [No Abstract]   [Full Text] [Related]  

  • 20. LU135252, an endothelin(A) receptor antagonist did not prevent pulmonary vascular remodelling or lung fibrosis in a rat model of myocardial infarction.
    Nguyen QT; Colombo F; Rouleau JL; Dupuis J; Calderone A
    Br J Pharmacol; 2000 Aug; 130(7):1525-30. PubMed ID: 10928953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.